Baseline levels (T0) of protein and mRNA for PIM-1, PIM-2, and PIM-3 in patients with RA, axSpA, and PsA who had not received any disease-modifying therapy were compared to patients who had previously received treatment with cDMARDs or corticosteroids. The gene discussed is PIM3; the disease is rheumatoid arthritis.